EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Vito Amodio,Rona Yaeger,Pamela Arcella,Carlotta Cancelliere,Simona Lamba,Annalisa Lorenzato,Sabrina Arena,Monica Montone,Benedetta Mussolin,Yu Bian,Adele Whaley,Marika Pinnelli,Yonina R Murciano-Goroff,Efsevia Vakiani,Nicola Valeri,Wei-Li Liao,Anuja Bhalkikar,Sheeno Thyparambil,Hui-Yong Zhao,Elisa de Stanchina,Silvia Marsoni,Salvatore Siena,Andrea Bertotti,Livio Trusolino,Bob T Li,Neal Rosen,Federica Di Nicolantonio,Alberto Bardelli,Sandra Misale,Yonina R. Murciano-Goroff,Bob T. Li

DOI: https://doi.org/10.1158/2159-8290.cd-20-0187

IF: 28.2

2020-08-04

Cancer Discovery

Abstract:Most patients with KRAS G12C –mutant non–small cell lung cancer (NSCLC) experience clinical benefit from selective KRAS G12C inhibition, whereas patients with colorectal cancer bearing the same mutation rarely respond. To investigate the cause of the limited efficacy of KRAS G12C inhibitors in colorectal cancer, we examined the effects of AMG510 in KRAS G12C colorectal cancer cell lines. Unlike NSCLC cell lines, KRAS G12C colorectal cancer models have high basal receptor tyrosine kinase (RTK) activation and are responsive to growth factor stimulation. In colorectal cancer lines, KRAS G12C inhibition induces higher phospho-ERK rebound than in NSCLC cells. Although upstream activation of several RTKs interferes with KRAS G12C blockade, we identify EGFR signaling as the dominant mechanism of colorectal cancer resistance to KRAS G12C inhibitors. The combinatorial targeting of EGFR and KRAS G12C is highly effective in colorectal cancer cells and patient-derived organoids and xenografts, suggesting a novel therapeutic strategy to treat patients with KRAS G12C colorectal cancer. Significance: The efficacy of KRAS G12C inhibitors in NSCLC and colorectal cancer is lineage-specific. RTK dependency and signaling rebound kinetics are responsible for sensitivity or resistance to KRAS G12C inhibition in colorectal cancer. EGFR and KRAS G12C should be concomitantly inhibited to overcome resistance to KRAS G12C blockade in colorectal tumors. See related commentary by Koleilat and Kwong, p. 1094 . This article is highlighted in the In This Issue feature, p. 1079

oncology

What problem does this paper attempt to address?

The paper aims to address the issue of the efficacy of KRAS G12C inhibitors in colorectal cancer (CRC) being inferior to that in non-small cell lung cancer (NSCLC). The study found that despite the presence of the same KRAS G12C mutation in CRC, these inhibitors are less effective. By comparing CRC and NSCLC cell models, researchers discovered that CRC cells are more dependent on the epidermal growth factor receptor (EGFR) signaling pathway and exhibit a stronger MAPK pathway rebound after using KRAS G12C inhibitors. Therefore, the study proposes that co-inhibition of EGFR and KRAS G12C can effectively overcome the resistance to KRAS G12C inhibitors in CRC. This strategy is not only effective in cell lines but also shows good results in patient-derived organoids and xenograft models, suggesting that combination therapy may become an effective method for treating KRAS G12C mutant CRC.